Achondroplasia Clinical Trials

Image of Children's Hospital & Research Center Oakland in Oakland, United States.
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

Active BMN 111: Daily Subcutaneous Injection Of 15 Ug/kg Of BMN 111for Achondroplasia

Any Age
All Sexes
This trial is testing a drug to see if it's safe and effective for children with achondroplasia, a form of dwarfism, until they reach their full adult height.
Phase 2
Waitlist Available
Children's Hospital & Research Center Oakland (+8 Sites)Medical Director MDBioMarin Pharmaceutical